31335results about "Fungi" patented technology

The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and / or treatment of acute and chronic inflammatory and other diseases.

Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. Thelower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways. This is achieved using a combination of engineering and / or selection of strains which: do not express certain enzymes which create the undesirable complex structures characteristic of the fungal glycoproteins, which express exogenous enzymes selected either to have optimal activity under the conditions present in the fungi where activity is desired, or which are targeted to an organelle where optimal activity is achieved, and combinations thereof wherein the genetically engineered eukaryote expresses multiple exogenous enzymes required to produce “human-like” glycoproteins.

The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and / or cellular tropisms as compared with current AAV vectors.

A biologically pure culture of a yeast of the species Metschnikowia fructicola. The yeast is identified as NRRL Y-30752 and is capable of inhibiting growth of a deleterious micro-organism on a portion of a plant to which a biologically effective amount of a culture of the yeast is applied. Further disclosed is a composition for use in protection of agricultural produce including a biologically effective amount of Metschnikowia fructicola and a carrier. Further disclosed is an article of manufacture including packaging material and the disclosed composition which is identified for use in protection of agricultural produce from a deleterious micro-organism. Further disclosed is a method of inhibiting growth of a deleterious micro-organism on a portion of a plant including applying at least one time an agriculturally effective amount of yeast of the genus Metschnikowia to the portion of a plant.